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The Lkb1 tumor suppressor exerts its biological
effects through phosphorylation and consequent
activation of the AMP kinase (AMPK) family. Exten-
sive genetic and biochemical evidence supports
a role for Lkb1 in cell cycle arrest, establishment of
cell polarity, and cellular energy metabolism. How-
ever, the role of Lkb1 and the AMPK family in b cell
function in vivo has not been established. We gener-
ated conditional knockout mice with a deletion of the
Lkb1 gene in the b cell compartment of pancreatic
islets; these mice display improved glucose toler-
ance and protection against diet-induced hypergly-
cemia. Lkb1/ b cells are hypertrophic because of
elevated mTOR activity; they also proliferate more
and secrete more insulin in response to glucose.
These data indicate that inhibiting Lkb1 activity in
b cells may facilitate b cell expansion and glucose
tolerance in vivo.
INTRODUCTION
Regulation of insulin secretion by the pancreatic b cell is critical
for the proper maintenance of glucose homeostasis. During
feeding, insulin secretion is triggered by elevations in blood
glucose and is modulated by incretin hormones (Drucker,
2006; Jia et al., 1995). Glucose-induced insulin secretion in-
volves glucose sensing (e.g., glucose uptake and retention medi-
ated by GLUT2 and GK) and events that lie at or downstream of
mitochondria (e.g., oxidation of glucose and other nutrients to
generate ATP, K-ATP channel closure, b cell membrane depolar-
ization, and extracellular calcium influx) (MacDonald et al., 2005;
Newgard and McGarry, 1995; Newsholme et al., 2007). Influx of
calcium ions into the cytoplasm from extracellular and intracel-
lular stores is a critical event that couples glucose stimulation
to insulin secretion. Impaired insulin response resulting fromCeldysfunction or loss of b cells underlies all forms of diabetes
(Mathis et al., 2001; Muoio and Newgard, 2008).
The Lkb1 gene (also known as Stk11) encodes a serine/threo-
nine protein kinase that was first described as a tumor
suppressor gene mutated in Peutz-Jeghers syndrome (PJS),
a familial form of cancer (Giardiello and Trimbath, 2006; Hem-
minki et al., 1998; Katajisto et al., 2007; Miyaki et al., 2000).
Consistent with a role for Lkb1 as a tumor suppressor, expres-
sion of Lkb1 induces G1 cell cycle arrest (Tiainen et al., 1999),
and Lkb1/+ mice are predisposed to developing hamartoma-
tous intestinal polyps associated with activation of mTOR kinase
(Bardeesy et al., 2002; Shaw et al., 2004b). Lkb1 functions in
a complex with the scaffold protein MO25 and the pseudokinase
STRAD (Baas et al., 2003; Boudeau et al., 2003; Boudeau et al.,
2004; Hawley et al., 2003; Milburn et al., 2004), exerting its
known biological effects via phosphorylation and consequent
activation of all members of the AMPK family (Lizcano et al.,
2004).
Given the diversity of biological roles attributed to the AMPK
family of kinases, Lkb1 has been implicated in a number of
distinct biological phenomena: tumor suppression, energy
metabolism via AMPK-TSC2-mediated mTOR inhibition and
activation of eEF2 kinase (Browne et al., 2004; Inoki et al.,
2003), and the establishment of cell polarity via AMPK1/2,
MARKs1–4, and Brsk1/SAD-B/Brsk2/SAD-A kinases (Baas
et al., 2004; Barnes et al., 2007; Kishi et al., 2005; Martin and
St Johnston, 2003; Watts et al., 2000; Lee et al., 2007; Mirouse
et al., 2007; Zhang et al., 2006; Zheng and Cantley, 2007).
Although Lkb1 null mice die at E8.5–11, indicating an essential
role for Lkb1 in development (Bardeesy et al., 2002; Jishage
et al., 2002; Miyoshi et al., 2002; Ylikorkala et al., 2001), the tar-
geted loss of Lkb1 in different settings, including skeletal muscle,
liver, and pancreas, has provided further evidence for Lkb1 as
a tumor suppressor and a critical regulator of cell polarity and
energy metabolism (Hezel et al., 2008; Katajisto et al., 2008;
Koh et al., 2006; Sakamoto et al., 2005; Sakamoto et al., 2006;
Shaw et al., 2004a).
AMPK is a central cell energy sensor that is activated via an
increase in the intracellular AMP:ATP ratio under low nutrientl Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Inc. 285
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Figure 1. Deletion of Lkb1 in Adult b Cells
(A) Adult Lkb1loxP/loxP mice carrying the Pdx1-CreERt2 transgene were injected with tamoxifen to induce b cell–specific deletion of Lkb1.
(B) QPCR analysis showing reduction of Lkb1 mRNA levels in total RNA from islets isolated from Lkb1loxP/loxP (L/L) and Lkb1loxP/loxP, Pdx1-CreERt2 (LABKO) mice.
RNA is pooled from 3 mice per genotype. Lkb1 mRNA levels are normalized to levels of 36B4 mRNA as internal control and are representative of two experiments.
All data are represented as mean ± SEM.
(C) Western blot analysis showing loss or reduction of Lkb1 protein from extracts of isolated islets from LABKO mice. CREB levels are shown as loading control.
(D) Pancreatic sections stained with insulin and Lkb1 antibodies reveal loss of Lkb1 in insulin-positive cells in LABKO mice, whereas all control (L/L) insulin-posi-
tive cells expressed Lkb1. Scale bar, 25 mm.
(E) Immunostaining of pancreatic sections of LABKO mice with a cocktail of antibodies to non–b cells (somatostatin/delta, glucagon/alpha, and pancreatic poly-
peptide/PP) reveals intact Lkb1 expression in these compartments. Merge of Lkb1 (green) and non–b cell (red) staining is shown at right. Scale bar, 25 mm.conditions (Hardie, 2007b). Given the involvement of AMPK in
exercise-dependent glucose uptake in muscle (Mu et al.,
2001), inhibition of gluconeogenesis in the liver (Hundal et al.,
2000; Iglesias et al., 2002), regulation by hormones leptin, resis-
tin, and adiponectin (Banerjee et al., 2004; Minokoshi et al., 2002;
Yamauchi et al., 2002), and activation in response to treatment
with the diabetes therapeutic metformin (Zhou et al., 2001), it
has been extensively studied as a potential target for treatment
of hyperglycemia (Zhang et al., 2009). With respect to energy
metabolism, Lkb1-Ampk function is required in the liver to inhibit
the gluconeogenic program driven by the CREB coactivator
Crtc2/Torc2; as such, Lkb1 agonists have been proposed to
be potential therapeutics for hyperglycemia associated with
type 2 diabetes (Shaw et al., 2005). However, activation of
AMPK has been reported to impair glucose-induced insulin
secretion and survival of pancreatic b cells and islets (da Silva
Xavier et al., 2000; Leclerc et al., 2004; Richards et al., 2005),
observations that suggest that inappropriate Lkb1 activity may
be deleterious for b cell function. Given the interdependence of
hepatic and pancreatic contributions to glucose metabolism, in
this study we sought to determine the role of Lkb1 in adult b cells
via conditional ablation of the Lkb1 gene.286 Cell Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier IRESULTS
Ablation of Lkb1 in Adult b Cells
Lkb1 is expressed in all epithelial cell lineages in both endocrine
and exocrine compartments from embryonic day E16.5 (Hezel
et al., 2008). To study Lkb1 function in adult animals and also to
avoid potential developmental complications due to the absence
of Lkb1, we employed a conditional gene ablation approach in
mice to inactivate the Lkb1 gene in mature b cells (Figure 1A). In
adult mice, Pdx1 expression is restricted within the islet to the
b cell compartment. We therefore bred Lkb1loxP/loxP mice to
Pdx1-CreERt2 transgenic mice that express the tamoxifen-
inducible Cre recombinase via the Pdx1 promoter (Gu et al.,
2002). Progeny with genotype Lkb1loxP/+, Pdx1-CreERt2 were
mated to Lkb1loxP/loxP mice to obtain Lkb1loxP/loxP, Pdx1CreERt2
mice and control Lkb1loxP/loxP littermates. The Cre system does
not elicit phenotypic changes from WT Fvb control mice (Hezel
et al., 2008; see also Figure S1 available online).
Cre activity was induced in 8- to 10-week-old Lkb1loxP/loxP,
Pdx1-CreERt2 male mice by IP injection of tamoxifen. After
1 week of tamoxifen treatment, we observed that Lkb1 mRNA
expression was reduced by 80% in islets from Lkb1loxP/loxP,nc.
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Knockout, or LABKO), compared with Lkb1loxP/loxP control (Lkb1
L/L, or L/L) mice, as measured by quantitative RT-PCR of total
RNA purified from isolated islets (Figure 1B). It is likely that unper-
turbed expression of Lkb1 in non-b islet cells (alpha, delta, epsilon,
and PP cells) explained the residual mRNA detected in total islet
RNAbyQPCR,aswe investigatebelow.Westernblottingofprotein
extracts prepared from isolated islets indicated nearly complete
loss of Lkb1 protein in islets from LABKO animals, consistent
with theobserved reduction inLkb1mRNA (Figure 1C). Immunoflu-
orescence staining of pancreatic sections from adult control mice
demonstrated that Lkb1 was expressed primarily in the islets
(Figure 1D). There was nearly a complete loss of staining in LABKO
pancreata, demonstrating the efficiency of CreERt2-mediated
Lkb1 gene recombination. Costaining with anti-Lkb1 and anti-
insulin antibodies demonstrated uniform absence of Lkb1 protein
in b cells in islets from LABKO mice. Acinar cells in sections from
both WT and LABKO animals were either negative or weakly posi-
tive for Lkb1 staining, consistent with the observed absence of
Lkb1 protein in acinar tissue in adult mice (Hezel et al., 2008). To
confirm that Lkb1 had been deleted exclusively from the b cell
compartment, we costained sections for Lkb1 along with a cocktail
of antibodies to glucagon (alpha cells), somatostatin (delta cells),
and pancreatic polypeptide (PP cells; Figure 1E) and observed
that these cell types still expressed Lkb1. These data confirm
that the Lkb1 deletion was specific to the b cell compartment,
and we conclude that any phenotypic alteration observed in
LABKO mice is due to the loss of Lkb1 in b cells.
Improved Glucose Tolerance in LABKO Animals
We next performed an analysis of the glucoregulatory system in
the LABKO animals. Before tamoxifen treatment, mice carrying
the Pdx1-CreERt transgene showed no difference in fasting or
random fed blood glucose levels (Figure 2A, left panel). After
tamoxifen treatment, LABKO animals displayed marginally lower
blood glucose levels than did controls when fasted or refed for
2 hr (Figure 2A, right panel). We next performed glucose toler-
ance tests to assess the dynamics of the response to glucose
in LABKO mice. Loss of Lkb1 significantly accelerated glucose
clearance by glucose tolerance test, compared with control L/
L mice (IPGTT; Figure 2B); Pdx-CreERt+ mice carrying one WT
Lkb1 allele demonstrated a normal IPGTT profile, indicating
that loss of Lkb1 underlies the improvement in glucose tolerance
(Figure S1). To determine the underlying cause of this enhanced
glycemic control, we measured plasma insulin levels in LABKO
animals after an overnight fast and 60 min of refeeding. Plasma
insulin levels of LABKO mice were more than 2-fold higher
than those of controls during both fasting and refeeding
(Figure 2C), indicating that enhanced basal and nutrient-stimu-
lated insulin secretion likely underlies the improved glucose
tolerance.
To provoke an increased functional response from the b cell
mass, LABKO and control mice were fed a high-fat diet for 16
weeks, a regimen that induces features of human metabolic
syndrome, including obesity, hyperglycemia, and insulin resis-
tance. After 16 weeks on a high-fat diet, control and LABKO
animals had indistinguishable body weights (Figure 2D), but
control mice displayed a progressive deficiency in glucose clear-
ance in IPGTT assays (Figure 2E). Remarkably, glucose toler-Ceance in the LABKO mice was similar to that in animals fed normal
diet (compare Figure 2E on high-fat diet to Figure 2B on normal
diet), indicating that loss of Lkb1 improves the capacity of the
b cell mass to facilitate restoration of euglycemia in this setting.
Glucose readings for L/L animals on high-fat diet were frequently
above the limit of glucometer detection (33.3 mM); thus, these
data would underestimate the effect of Lkb1 on lowering blood
glucose in this context. In contrast, immunohistochemical anal-
ysis suggested that Lkb1 protein levels were increased in islets
of L/L control mice fed a high-fat diet for 16 weeks, compared
with age-matched controls (Figure 2F). Furthermore, Lkb1
protein was significantly increased in extracts of islets isolated
from ob/ob mice, compared with control B6 mouse islets
(Figure 2G), indicating that Lkb1 accumulation correlates with
glucose intolerance in two distinct models of type 2 diabetes.
Loss of LKB1 in Adult Islets Increases b Cell Mass
and Insulin Secretion
To determine whether a defect in insulin storage contributed to
the hyperinsulinemia observed in fed Lkb1 mutant mice, we
measured insulin content in islets isolated from LABKO mice.
Insulin content of LABKO islets (Figure 3A) and the b cell mass
doubled in LABKO animals (Figure 3B), whereas alpha cell
mass was unaffected (Figure 3C). Quantitation of insulin staining
from pancreatic sections (shown in Figure 3B) confirmed the
increase in insulin staining in LABKO islets (Figure S2) and
revealed a 20% increase in islet size (Figure S3). Taken together,
these data indicate that increased insulin accumulation in
Lkb1-deficient b cells and expansion of b cell mass may underlie
the improved glucose clearance. To determine whether the
LABKO islets displayed a corresponding increase in glucose-
stimulated insulin secretion and to investigate the cell autonomy
of the phenotype, we performed static incubation GSIS assays
using isolated islets from LABKO and control mice 1 week after
tamoxifen injection. Basal insulin secretion increased by 3-fold in
LABKO islets, and, after 1 hr of stimulation with 20 mM glucose,
LABKO islets secreted 40% more insulin than did control islets
(Figure 3D). We next performed islet perifusion studies to eval-
uate the dynamics of insulin secretion in response to glucose.
Consistent with the static incubation data, we observed an
increase in total secreted insulin from LABKO islets following
20 mM glucose treatment (Figure 3E). In particular, we noted a
significant increase in first- and second-phase insulin secretion
from LAKBO islets that could not be accounted for by the in-
crease in insulin content alone, which is suggestive of enhanced
glucose coupling efficiency in islets lacking Lkb1.
AMPK is activated under conditions of high AMP:ATP ob-
served during conditions of nutrient exhaustion, hypoxia, and
ischemia, among others (Hardie, 2003). AMP binding to the
AMPK g subunit and Thr172 phosphorylation of the alpha
subunit by Lkb1 or other AMPKK is required to achieve full
AMPK activity (Lizcano et al., 2004). As a consequence, AMPK
activity is attenuated in settings where Lkb1 protein is reduced.
To determine whether P-Ampk activity in islets may be controlled
in accordance with fluctuations in glucose across the fasted-fed
transition (6–11 mM), we stimulated islets cultured in low glucose
(2.8 mM) with increasing glucose concentrations up to 15 mM
and monitored changes in the level of P-Ampk. Comparison of
the levels of P-Ampk at 7.5 mM glucose and higher (fed range)ll Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Inc. 287
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Figure 2. Enhanced Glucose Tolerance in LABKO Animals
(A) Blood glucose levels of fasted and random fed control (L/L) and LABKO mice were measured prior to tamoxifen treatment (left panel; n = 5) or from fasted or
refed (2 hr) animals 1 week after tamoxifen treatment (right panel; *p < 0.05 for fasted mice; n = 9 L/L, n = 17 LABKO). All data are mean ± SEM.
(B) Glucose tolerance test (2 mg glucose/g, IP injection) for tamoxifen treated L/L and LABKO mice; n = 9 for both groups. Blood glucose concentrations were
determined at indicated times. Area under the curves shown at right; *p < 0.02.
(C) Plasma insulin levels after 60 min of refeeding in control (L/L; n = 6) and LABKO mice (LABKO; n = 12). *p < 0.03 for fasted; ***p < 0.001 for refed.
(D) Weights of control (L/L) and LABKO animals on high-fat diet for 16 weeks.
(E) Glucose tolerance test of control (L/L) and LABKO animals on high-fat diet for 16 weeks. Area under the curve shown at right; ***p < 0.003.
(F) Immunostaining of pancreatic sections on control mice with anti-LKB1 antibody after 18 weeks on normal or high-fat diet.
(G) Western blot analysis of Lkb1 protein levels in extracts of isolated islets from control C57BL/6J and B6.V-Lepob/J (‘‘ob/ob’’) mice, compared with B6 control
mice. Quantitation of Lkb1 levels normalized to actin loading control shown at right.to those found at 5 mM (fasted range) revealed a 60%–80%
reduction in levels of P-Ampk (Figure S4). Examination of
P-Ampk levels in glucose-starved islets from LABKO mice
revealed a similar reduction in P-Ampk levels (Figure 3F). Impor-
tantly, the absence of Lkb1 completely prevented pharmacolog-
ical activation of Ampk in LABKO islets treated with the
Ampkactivator 5-aminoimidazole-4-carboxamide-1-b-D-riboside
(AICAR; Figure S5), indicating that Lkb1 is the principal AMPK
kinase in islet b cells. Taken together, we conclude that AMPK
activity is regulated by physiological changes in glucose concen-
tration observed during feeding and fasting, and that Lkb1 is the
principal upstream Ampk kinase in islet b cells.
Loss of Ampk Alpha 1 Promotes Insulin Accumulation
and Basal Secretion
To facilitate examination of the improved insulin secretion
phenotype, we attempted to model LABKO islets using siRNA-288 Cell Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Imediated knockdown of Lkb1 in the glucose-responsive cell
line, MIN6. Western blot analysis confirmed reduction of Lkb1
protein by 90% in cells transfected with siRNA targeting Lkb1
relative to nonspecific control (Figure 4A, compare lanes 1 and
2), as well as a 50% reduction in P-Ampk levels in low glucose
that was enhanced in the presence of glucose (Figure 4A,
compare lanes 2 and 4; quantitation is shown in Figure S6).
Thus, the effect of Lkb1 loss on Ampk activity in islets can be
recapitulated in Lkb1 knockdown MIN6 cells. Consistent with
the results from LABKO islets, Lkb1 knockdown resulted in a
2-fold increase in insulin content (Figure 4B) and a 2-fold
increase in insulin secretion in low glucose (Figure 4C, left panel).
When stimulated with 20 mM glucose, Lkb1 knockdown cells
similarly secreted nearly 2 times more insulin (80 ng insulin/
well, compared with 45 ng/well for control cells). When the
amount of secreted insulin was normalized to content, the
increase in secretion appeared to result largely, although notnc.
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Figure 3. Loss of Lkb1 in Islets Enhances Insulin Secretion
(A) Insulin content in islets isolated from LABKO and control mice (n = 5; *p < 0.03). All data are mean ± SEM.
(B) Left, insulin staining of pancreatic sections from control L/L and LABKO mice. Right, histogram showing b cell mass (mg per pancreas) in control L/L and
LABKO islets (n = 6–7; *p < 0.02).
(C) Left, glucagon staining of pancreatic sections from L/L and LABKO mice. Right, histogram showing alpha cell mass in control L/L and LABKO mice (n = 5–6;
p < 0.7).
(D) Increased insulin secretion in LABKO islets. Twenty islets per genotype were incubated in low glucose (1 mM) and stimulated with 20 mM glucose for 1 hr at
37C. Supernatants were analyzed for insulin content by HTRF assay. Data shown are representative of 4 independent experiments with islets from 4–8 mice per
genotype are shown. Low glucose, *p < 0.04; high glucose, ***p < 0.002.
(E) Top: Glucose-stimulated insulin secretion assay by islet perifusion from L/L and LABKO mice. Islets incubated in 2.8 mM glucose were stimulated with 20 mM
glucose and then 45 mM KCl, as indicated. Insulin content in collected fractions was determined by HTRF assay and presented as secreted insulin normalized to
islet insulin content percentage of insulin secreted; n = 3 animals per genotype). Data presented are from one of three independent experiments. Bottom: Area
under the curves. ***p < 0.0005; **p < 0.004. For KCl treatment, p = 0.3.
(F) Western blot analysis of P-Ampk and total Ampk levels in isolated islets from control (L/L) and LABKO animals. Blots for Lkb1 and ATF1 loading control are
shown.entirely, from an increase in insulin stores (Figure 4C, right panel).
Consistent with this finding, treatment of control and Lkb1
knockdown cells with the depolarizing agent KCl resulted in
unchanged insulin secretion when normalized to content.
Phenotypic alterations due to the loss of Lkb1 are expected to
result from the net loss of the activities of all members of the
AMPK family. To investigate the enhanced basal insulin secre-
tion phenotype seen in Lkb1 knockdown cells, we transfected
siRNA targeting those Ampk family members that have, to
date, been implicated in metabolic control: Ampk a1, Ampk a2,Ceand Mark2. Western blot analysis using an antibody that recog-
nizes both Ampk a1 and a2 demonstrated efficient knockdown
of Ampk a1 but not Ampk a2, indicating that Ampk a2 is likely
expressed at lower amounts than is Ampk a1 in MIN6 cells
(Figure 4D). Interestingly, knockdown of Ampk a1, but not
Ampk a2 or Mark2, recapitulated the effect of Lkb1 knockdown
on both insulin content (Figure 4E) and insulin secretion
(Figure 4F), indicating that loss of Ampk a1 promotes insulin
accumulation and secretion. Similarly, the observed increase in
insulin secretion in Lkb1 and Ampka1 knockdown cellsll Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Inc. 289
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Figure 4. AMPK a1 Knockdown Promotes Insulin Accumulation and Secretion
(A) Western blot analysis of P-Ampk, total Ampk, and Lkb1 levels in MIN6 cultures treated with control or Lkb1 siRNA in the presence of low (1 mM) or high (20 mM)
glucose. b actin loading control is shown.
(B) Insulin content in Lkb1 knockdown and control siRNA treated cells cultured in 1 mM glucose; ***p < 0.001. All data are represented as mean ± SEM.
(C) Left, insulin secretion in Lkb1 knockdown and control siRNA-treated MIN6 cells cultured in low (1 mM; ***p < 0.00001) or high (20 mM; **p < 0.02) glucose, or
stimulated with 45 mM KCl (*p < 0.05) for 1 hr. Right, histogram showing insulin secretion values normalized to insulin content (***p < 0.001). Data in (B) and (C) are
representative of at least 3 experiments.
(D) Western blot analysis of Lkb1, Ampka1/a2, and Mark2 levels in MIN6 cultures treated with the indicated siRNA duplexes. b actin loading control is
shown.
(E) Insulin content in MIN6 cells transfected with the indicated siRNA duplexes and cultured in 1 mM glucose. P values for insulin readings, compared with control
siRNA, were as follows: Lkb1, **p < 0.02; Ampka1, ***p < 0.004, and Ampka1 and a2, **p < 0.01.
(F) Insulin secretion in Ampk a1 knockdown and control siRNA-treated MIN6 cells cultured in low 1 mM glucose or stimulated with 20 mM glucose for 1 hr. Lkb1,
***p < 0.00005; Ampk a1, ***p < 0.00008; and Ampk a1 and a2, **p < 0.02. Data in (E) and (F) are representative of at least 3 experiments.
(G) Lkb1 knockdown cells display an accelerated response time in the increase of intracellular calcium concentration of control (top left) and Lkb1 knockdown
cells (bottom left) cultured in 1 mM or 20 mM glucose. Treatment with 45 mM KCl depolarization stimulus is indicated. The latency is marked with a red bar for
clarity. Right, Histogram showing reduction in Ca2+ influx latency in LABKO cells. Data are ± SEM of three independent experiments; *p < 0.03.appeared to result largely from increased insulin content. The
small enhancement in insulin secretion in Lkb1 knockdown cells
stimulated with 20 mM glucose and the enhanced first-phase
secretion seen in perifusion studies (Figure 4C, right panel)
raised the possibility that loss of Lkb1 may also improve the
coupling of glucose stimulation to insulin secretion. To address
this possibility, we performed calcium imaging experiments in
MIN6 cells. Analysis of cytosolic calcium revealed that basal
levels of intracellular Ca2+ were comparable in control and
Lkb1 knockdown MIN6 cells, indicating that control mechanisms
governing Ca2+ content are preserved under low-glucose condi-
tions (data not shown). However, glucose induced a more rapid
response in the Lkb1 cells than in controls (Figure 4G), which is
consistent with an improvement in glucose sensing.290 Cell Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier IEnhanced b Cell Proliferation, Hypertrophy,
and mTOR Pathway Activation in the Absence of Lkb1
To determine whether enhanced b cell proliferation in the LABKO
mice also contributed to the increase in islet size (Figure S2), we
performed BrdU incorporation studies (Figure 5A). Quantitation
of BrdU+ cells in islets of LABKO animals revealed a 2.7-fold
increase in the number of BrdU+ insulin+ cells per islet (Fig-
ure 5B), indicating that loss of Lkb1 activity also enhances
recruitment of b cells into the cell cycle. Examination of pancre-
atic sections stained with hematoxylin and eosin (H&E) also
revealed larger b cells and an altered distribution of nuclei
within the b cell compartment (Figure 5C), alterations consistent
with a role for Lkb1 in homeostatic maintenance of b cell size
and architecture (Dhawan et al., 2007; Hezel et al., 2008).nc.
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Figure 5. Lkb1 Regulates b Cell Proliferation, Size, and Architecture and Activates mTor Signaling
(A) Representative immunofluorescence staining for BrdU (green), insulin (red), and DAPI (blue) in pancreatic sections from control (L/L) and LABKO mice injected
with BrdU. These were used to evaluate the b cell proliferation index shown in (B).
(B) Histogram showing number of double BrdU+, insulin+ cells in L/L and LABKO mice (n = 5–6; *p < 0.03). All data are represented as mean ± SEM.
(C) H&E staining of islets in pancreatic sections from L/L and LABKO mice. Two islets per genotype are shown. Bar, 50 mm.
(D) H&E staining of islets in pancreatic sections from WT and Mark2/ mice. Bar, 50 mm.
(E) Histogram showing number of b cells per 10,000 um2 (area of a medium-sized islet) in pancreatic sections from L/L or LABKO mice. Effect of low dose
rapamycin treatment on b cell size is shown (n = 3–4; *p < 0.04; ***p < 0.000004).
(F) Western blot analysis showing elevation in S6K phosphorylation, indicative of mTor pathway activation, in extracts of islets isolated from LABKO mice
18 weeks after tamoxifen injection. Western blots were reprobed with antibodies to total S6K, P-Ampk, Ampk, Lkb1, and b actin.Cell Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Inc. 291
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a similar alteration in nuclear positioning as seen in LABKO
islets, indicating that loss of Mark2 activity in the LABKO islets
underlies, at least in part, the observed morphological change
(Figure 5D). We also observed what appeared to be larger
b cells in LABKO islets. When this was quantitated, we found
a 25% reduction in the number of b cells per unit area in
LABKO islets, indicating that b cells lacking Lkb1 are larger
than controls (Figure 5E).
Ampk activation promotes catabolic events and inhibits
anabolic activities, such as protein translation, which is directly
linked to the growth state of the cell and controlled by mTOR
kinase. To determine whether increased mTor activity is required
for b cell hypertrophy in islets of LABKO mice, we treated animals
with a low dose of rapamycin to inhibit mTOR kinase activity
in vivo. We observed that 7 days of rapamycin treatment in-
creased cell number per unit area in control L/L mice and was
also sufficient to revert the b cell hypertrophy in LABKO animals
(Figure 5E). Consistent with this finding, in LABKO islets we
observed increased phosphorylation of the mTor target S6
kinase, which serves as a readout for the activity of the protein
translation machinery and of cell growth (Figure 5F). Taken
together, these data are consistent with the idea that loss of
Ampk activity in cells lacking Lkb1 underlies the b cell hyper-
trophy in the LABKO islets.
DISCUSSION
It is becoming increasingly clear that the diverse biological
consequences of loss of Lkb1 activity, including tumor suscep-
tibility and loss of polarity, result from dysfunction of members
of the AMPK family, including AMPK itself. Our data provide
further evidence for the emerging concept that there is an inti-
mate connection between glucose metabolism/energy balance
and polarity under control of Lkb1, here in pancreatic islets.
b cell mass is governed by at least four parameters, including
proliferation, apoptosis, cell size, and neogenesis (Ackermann
and Gannon, 2007). We have found that, within 7–10 days after
acute Lkb1 deletion, b cell mass is increased, insulin accumu-
lates in islet b cells, and its secretion is enhanced, indicating
that these are highly dynamic processes subject to fine control
by Lkb1. Importantly, the improvement in glucose clearance
in vivo is preserved under high-fat diet challenge and sustained
for at least five months after loss of Lkb1. Moreover, the accumu-
lation of Lkb1 protein in islets of mice rendered glucose intolerant
as a result of either leptin mutation (ob/ob mice) or excessive
caloric intake supports the idea that Lkb1 may serve to antago-
nize b cell function in these settings. Future work will address the
potential for regulation of apoptosis and neogenesis by Lkb1.
Although the role of Ampk in b cell function in vivo has not been
established, and defining a precise role for Ampk in insulin secre-
tion has been controversial (da Silva Xavier et al., 2000; Gleason
et al., 2007; Leclerc et al., 2004; Richards et al., 2005), our data
are consistent with Ampk a1 having an inhibitory effect on insulin
accumulation and secretion in the basal state. Although Ampk a1
knockout mice display normal glucose tolerance (Viollet et al.,
2003), this may be due to the combined effects of loss of
Ampk a1 from other tissues that influence glucose metabolism.
That Lkb1 is the critical upstream regulator of Ampk activity in292 Cell Metabolism 10, 285–295, October 7, 2009 ª2009 Elsevier Ib cells is reinforced by the activation of mTOR pathway in
LABKO islets and the Lkb1 phenocopy seen in Ampk a1 knock-
down cells. The increase in islet insulin content is reflected in the
hypertrophy of b cells lacking Lkb1, which, together with the
increased proliferative index, results in a doubling of b cell
mass in LABKO mice, observations reminiscent of mice with
a deletion of Tsc2 in the b cell (Rachdi et al., 2008). Because
loss of Lkb1 removes a break on translation via AMPK-mTOR
that would normally exist under nutrient deprivation (Shaw
et al., 2004a), we suggest that the Lkb1:Ampk signaling cassette
in mature b cells serves to restrain insulin secretion by limiting
insulin stores. Indeed, Ampk activity in cultured b cell lines is acti-
vated by pioglitozone and metformin, both of which attenuate
insulin secretion (Lamontagne et al., 2009; Leclerc et al., 2004).
Although the increased insulin secretion with loss of Lkb1
in vivo appears to result predominantly from increased b cell
mass and, in vitro, from increased insulin content, there appears
to be some contribution resulting from improved coupling of
secretion to glucose, as revealed by enhanced first-phase secre-
tion in perifused islets and the accelerated calcium influx
following glucose stimulation in MIN6 cells. Notably, impaired
first-phase secretion is a hallmark of type 2 diabetes (Mitrakou
et al., 1992); our data suggest that inhibiting Lkb1 in b cells
may help to overcome such a deficiency.
A recent study reported a whole pancreas knockout of Lkb1 in
mice, characterized by acinar cell degeneration and pancreatic
insufficiency, development of a PJS-associated tumor type
(serous cystadenomas), smaller islets with a normal morphology
and balance of cell types, and improved glucose tolerance at 6
weeks of age. In carcinogenesis, loss of Lkb1 promotes cell
proliferation as a result of failure of the maintenance of cytoskel-
etal integrity (Hezel et al., 2008). b cells lacking Lkb1 showed
alterations in nuclear distribution, indicating that Lkb1 signaling
contributes to steady-state determination of nuclear positioning
in the islet. Of the candidates in the AMPK family that may
mediate the positioning defect—AMPK1/2, MARK, and SAD
kinases, all of which have been implicated in establishment of
cell polarity (reviewed in Hurov and Piwnica-Worms, 2007)—
H&E staining of pancreatic sections from Mark2/ mice indi-
cates that the Lkb1-Mark2 pathway, at least in part, governs
this phenotype. Although the precise reason for this effect is
unknown, one possibility is that mature, nondividing b cells are
functionally polarized, and this information is lost in the absence
of Lkb1. Given the concomitant increase in the proliferative index
in b cell populations lacking Lkb1, this finding suggests that the
loss of polarity in the absence of Lkb1 may help to promote
proliferation. It will be of interest to determine whether prolifer-
ating cells undergo structural alterations that are governed by
these polarity genes, which would indicate that cell polarization
may serve to restrain proliferation in contexts where b cell expan-
sion is compromised.
The absence of Lkb1 from the liver during feeding permits
unrestrained gluconeogenesis owing to a failure to inhibit
CRTC2:CREB activity (Shaw et al., 2005). We conclude that
the same pathway in liver and endocrine pancreas acts with
respect to glucose metabolism in a diametrically opposite
fashion at the level of the whole organism. AMPK has attracted
attention as a potential target for treatment of type 2 diabetes
(Hardie, 2007a), largely because of its effects on liver andnc.
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ulus-coupled insulin secretion is controversial (da Silva Xavier
et al., 2003; Gleason et al., 2007; Richards et al., 2005), but
given the complete inactivation of Ampk in glucose-stimulated
b cells, it is unlikely to play a role in acute regulation of insulin
secretion. Our data indicate that loss of Lkb1 and AMPK/
mTOR activity in b cells promotes responses from the b cell
mass, including b cell proliferation, cell growth, and generating
a fertile soil for enhanced insulin secretion, all of which are
consistent with the goals of b cell–focused therapies for type 1
and type 2 diabetes. Furthermore, our data indicate that inhibi-
tion of pancreatic Lkb1 with small molecule antagonists may
increase b cell mass, thereby providing therapeutic benefit for
hyperglycemia.
EXPERIMENTAL PROCEDURES
Mice
Lkb1loxP/loxP (FVB/n background; Hezel et al., 2008) and Pdx-CreERt2
mice (ICR background; kind gift of D. Melton) were mated to generate
Lkb1loxP/loxP, Pdx-CreERt2+ mice. The Pdx-CreERt2 mice were backcrossed
three times onto FVB/n background and then were intercrossed. To induce
Lkb1 gene ablation, 5 mg of tamoxifen (Sigma) per 40 g of body weight was
injected IP every second day for a total of 3 injections. Unless otherwise stated,
analyses were performed 5–10 days after the last tamoxifen injection. For high-
fat diet studies, mice were fed normal laboratory diet or high-fat diet (45 kcal%
fat; Open Source Diets) for 16 weeks. Mark2/EMK+/ mice were the kind gift of
H. Piwnica-Worms. All procedures involving mice were approved by the
Animal Care Committee of the University of Ottawa.
Glucose Tolerance and Insulin Tests
Animals were fasted overnight, and their fasting level of blood glucose was
evaluated with an Ultra OneTouch glucometer (Lifescan). Mice were then in-
jected IP with 2 mg/g of body weight (normal diet) and 1.5 mg/g of body weight
of glucose, and blood glucose and insulin levels were measured at the
indicated times. Plasma insulin levels were measured by ELISA using an ultra-
sensitive mouse insulin kit (Crystal Chem). Statistical significance for all data
was determined using Student’s t test; p values < 0.05 were considered signif-
icant. Significance is indicated in all figures as follows: *p < 0.05, **p < 0.01,
and ***p < 0.005.
Immunostaining
Pancreata from 4 Lkb1loxP/loxP and 4 Lkb1loxP/loxP, Pdx-CreERt2 mice were
isolated after perfusion with fixative (4% PFA in PBS), weighed, and stored
in fixative overnight at RT. Sections were treated in an Antigen Unmasker
(Pickcell) and stained with anti-LKB1 antiserum raised against the C terminus
of mouse Lkb1 (1:100), anti-insulin (1:200, DAKO), somatostatin/glucagon/PP
antibody cocktail (all at 1:200, DAKO), and revealed using HRP- or Alexa dye-
conjugated secondary antibodies for multiple labeling (Invitrogen). Sections
were mounted in Vectashield with DAPI (Vector Labs), and images were
captured using a Zeiss AxioSkop2 microscope fitted with a CCD camera.
For b cell and a cell mass measurements, three serial sections of 4 mm were
prepared from each pancreas at 100 mm apart. One section from each level
was stained with insulin (Biomed Diagnostics, 1:200) or glucagon and HRP-
conjugated secondary antibodies using DAB as chromogen. Hormone-posi-
tive areas in three sections were quantified using Aperio Imagescope software
by dividing the total insulin-positive area by the total area and multiplying this
value by the pancreas weight.
b Cell Size and Proliferation
To calculate the mean size of individual b cells, the b cell area (marked by stain-
ing with insulin antibodies) was divided by the number of nuclei in insulin+ cells,
counting 3 islets in 6 sections per mouse and 4–5 mice per genotype per treat-
ment. Data are presented as the number of b cells per 10,000 mm2, the size of
an average-sized islet. Rapamycin (0.6 mg/kg; LC Laboratories) was injectedCeevery second day for a total of 3 injections starting 1 day after the last tamox-
ifen injection. For BrdU incorporation studies, animals were injected at 8 weeks
with tamoxifen and 10 days later with 0.1 mg/g of body weight BrdU in PBS for
6 hr, perfused with 4% PFA, and processed for staining with anti-insulin and
anti-BrdU (1:150, Sigma) antibodies. The number of insulin+, BrdU+ cells in
a minimum of 1500 total insulin+ cells per pancreas was determined and
presented as the number of BrdU+ b cells/1000 b cells.
RNA Interference
MIN6 cells (p. 21–30) were cultured in DME plus 10% FCS plus antibiotics
containing 100 mM bmercaptoethanol. siRNAs were transfected into cells
using 1.1 ml Dharmafect 1 (Dharmacon) or 1 ml RNAiMAX (Invitrogen) per
well. On day 0, 1.83 105 cells (for Dharmafect) or 1.03 105 cells (for RNAiMAX)
were seeded in 48-well plates and transfected with 40 nM of the indicated
siRNA (Smartpool, Dharmacon) or control siRNA at the time of seeding.
Medium was changed on days 1 and 2 prior to GSIS analysis on day 3.
Glucose-Stimulated Insulin Secretion (GSIS)
Twenty-four hours after isolation, 20 size-matched small and medium islets were
cultured in RPMI and were equilibrated with Krebs Ringer Buffer (KRB; 128 mM
NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 5 mM
NaHCO3, 10 mM HEPES, and 0.1% BSA) plus 1 mM glucose for 30 min, prior
to incubation in 500 ml KRB plus 1 mM glucose for 1 hr. The SN was removed
and stored, and islets were stimulated with 500 ml of KRB plus 20 mM glucose
for 1 hr. All steps were performed at 37C in a tissue culture incubator. For islet
perifusion, 50 small islets per genotype were preincubated in KRB plus 2.8 mM
glucose for 45 min, following which 1 ml fractions were collected from islets in
KRB plus 2.8 mM or 20 mM glucose. Islets were depolarized with 45 mM KCl.
For MIN6 experiments, cells in 48-well plates were first equilibrated with
250 ml KRB plus 1 mM glucose for 1 hr, and then were incubated in KRB plus
1 mM glucose for 1 hr (basal). Cells were stimulated with KRB plus 20 mM
glucose or KRB plus 45 mM KCl for 1 hr. Three independent wells were used
per condition. For all experiments, total insulin was harvested by acid-ethanol
extraction overnight. Insulin measurements were performed by HTRF assay
(Cisbio) for GSIS experiments or by ELISA (Crystal Chem) for serum insulin.
Western Blotting
Western blots were performed as described elsewhere (Screaton et al., 2004);
80–100 isolated islets were starved with 2.8 mM glucose for 2 hr then treated
with the indicated concentrations of glucose for 1 hr prior to lysis directly in
Laemmli sample buffer. Antibodies used were Lkb1 (Santa-Cruz, 1:500),
GAPDH (Advanced Immunochemical Inc., 1:20,000), b-actin (Abcam,
1:10,000), ATF-1 (Cell Signaling Technology, 1:1,000), pThr172-AMPK (1:500),
AMPK (1:1,000), pThr389-S6K (1:1000) s6K (1:1000), pT56 eEF2 (1:1000), and
eEF2 (1:1000).
Measurement of Intracellular Free Ca2+ Concentration ([Ca2+]i)
[Ca2+]i was measured using the fluorescent probe fura-2AM (Molecular
Probes) as described elsewhere (Tabet et al., 2004) with the following modifi-
cations: on the day of the study, the culture medium was replaced with
prewarmed KRB containing 1 mM glucose. Cells were loaded with fura-2AM
dissolved in DMSO containing 0.02% pluronic F-127 (Molecular Probes) at a
final concentration of 4 mM for 30 min at 37C in a humidified incubator. Under
these conditions, ratiometric fluorescence cell images are homogeneous, indi-
cating no significant dye compartmentalization. Loaded cells were washed at
RT and used after a 5–10 min stabilization period. Coverslips were placed in
a stainless steel chamber of an inverted microscope (310 objective) with
a Stallion High Speed Digital Microscopy Workstation imaging system (Slide-
book, Zeiss). Fura-2AM loaded cells were excited at 340 and 380 nm, and their
emission at 510 nm was monitored. [Ca2+]i responses were measured in cells
exposed to KRB plus 20 mM glucose for 10 min. Latency data are derived from
calcium traces of >50 MIN6 cells per field.
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